TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer

International Journal of Cancer

Volumn 138, Issue 2, 2016, Pages 489-496

  Wang, Yuxia ^a   Xu, Ye ^a   Chen, Jiuan ^a   Ouyang, Tao ^a   Li, Jinfeng ^a   Wang, Tianfeng ^a   Fan, Zhaoqing ^a   Fan, Tie ^a   Lin, Benyao ^a   Xie, Yuntao ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

breast cancer; neoadjuvant chemotherapy; TP53 mutation

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; PROTEIN P53;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENETICS; HUMAN; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MUTATION; NEOADJUVANT THERAPY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84955723750     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29715     Document Type: Article

References (28)

1. Rastogi P, Anderson SJ, Bear HD, et al., Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-85.
2. Mauri D, Pavlidis N, Ioannidis JP., Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 188-94.
3. Vousden KH, Prives C., Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-31.
4. Goh AM, Coffill CR, Lane DP., The role of mutant p53 in human cancer. J Pathol 2011; 223: 116-26.
5. Soussi T, Dehouche K, Beroud C., p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat 2000; 15: 105-13.
6. Borresen-Dale AL., TP53 and breast cancer. Hum Mutat 2003; 21: 292-300.
7. Petitjean A, Mathe E, Kato S, et al., Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-9.
8. Muller PA, Vousden KH., p53 mutations in cancer. Nat Cell Biol 2013; 15: 2-8.
9. Brosh R, Rotter V., When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9: 701-13.
10. Oren M, Rotter V., Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010; 2: a001107.
11. Falette N, Paperin MP, Treilleux I, et al., Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res 1998; 58: 1451-5.
12. Olivier M, Langerod A, Carrieri P, et al., The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006; 12: 1157-67.
13. Aas T, Borresen AL, Geisler S, et al., Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2: 811-1 4.
14. Berns EM, Foekens JA, Vossen R, et al., Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 2000; 60: 2155-62.
15. Kandioler-Eckersberger D, Ludwig C, Rudas M, et al., TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000; 6: 50-6.
16. Geisler S, Lonning PE, Aas T, et al., Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61: 2505-12.
17. Bertheau P, Plassa F, Espie M, et al., Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002; 360: 852-4.
18. Bertheau P, Turpin E, Rickman DS, et al., Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 2007; 4: e90.
19. Lehmann-Che J, Andre F, Desmedt C, et al., Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist 2010; 15: 246-52.
20. Gluck S, Ross JS, Royce M, et al., TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine +/- trastuzumab. Breast Cancer Res Treat 2012; 132: 781-91.
21. Eikesdal HP, Knappskog S, Aas T, et al., TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy. Acta Oncol 2014; 53: 1347-55.
22. Wahl AF, Donaldson KL, Fairchild C, et al., Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996; 2: 72-9.
23. Bonnefoi H, Piccart M, Bogaerts J, et al., TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 2011; 12: 527-39.
24. Jackson JG, Pant V, Li Q, et al., p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012; 21: 793-806.
25. Varna M, Lehmann-Che J, Turpin E, et al., p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors. Int J Cancer 2009; 124: 991-7.
26. Geisler S, Borresen-Dale AL, Johnsen H, et al., TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 2003; 9: 5582-8.
27. Multani AS, Li C, Ozen M, et al., Paclitaxel and water-soluble poly (L-glutamic acid)-paclitaxel, induce direct chromosomal abnormalities and cell death in a murine metastatic melanoma cell line. Anticancer Res 1997; 17: 4269-74.
28. O'Connor PM, Jackman J, Bae I, et al., Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57: 4285-300.